VTL Vital Therapies Inc.

4.90
+0.15  (3%)
Previous Close 4.75
Open 4.80
Price To book 2.82
Market Cap 206816142
Shares 42,207,376
Volume 229,745
Short Ratio 17.04
Av. Daily Volume 159,555

SEC filingsSee all SEC filings

  1. 8-K - Current report 171070243
  2. 10-Q - Quarterly report [Sections 13 or 15(d)] 171005324
  3. 8-K - Current report 171005260
  4. S-8 - Securities to be offered to employees in employee benefit plans 17874636
  5. 8-K - Current report 17867776

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 VTI-208 trial failed. New VTI-308 trial initiated May 2016. Data due mid 2018.
VTI-308
Alcohol-induced liver decompensation, or AILD
Terminated September 2015 in order to reduce costs
ELAD (VTI-210)
Severe acute alcoholic hepatitis
Terminated September 2015 in order to reduce costs
ELAD (VTI-212)
Fulminant hepatic failure, or FHF, or surgery-induced acute liver failure, or SILF